In human cohorts, higher circulating ANGPTL4 concentrations have been observed in individuals with metabolic syndrome or type 2 diabetes compared with healthy controls [17,18], whereas patients with hepatic steatosis may exhibit lower plasma ANGPTL4 levels, potentially reflecting diminished LPL inhibition and increased hepatic fatty acid influx [19]. The gene discussed is LPL; the disease is Hepatic steatosis.